The case for using 5-aminosalicyclates in Crohn's disease: Pro

Stephen B. Hanauer*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations

Abstract

Mesalamine has a well-established role in the management of ulcerative colitis. However, its role in the management of Crohn's disease (CD) is less clear. Studies evaluating its therapeutic value in CD have produced both positive and negative results. Meta-analyses have not clarified the situation, possibly because they have combined studies of different design. This debate critically examines the evidence for and against the use of mesalamine in CD.

Original languageEnglish (US)
Pages (from-to)609-612
Number of pages4
JournalInflammatory bowel diseases
Volume11
Issue number6
DOIs
StatePublished - Jun 2005

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Fingerprint

Dive into the research topics of 'The case for using 5-aminosalicyclates in Crohn's disease: Pro'. Together they form a unique fingerprint.

Cite this